Abstract
Reactivation of Multiple Sclerosis (MS) activity has been described after fingolimod
cessation. Because of its contra indication during pregnancy, switch towards lower
efficacy treatments are frequent in MS patients with childbearing desire but expose
them to a risk of disease reactivation.
In this retrospective study including 44 women with MS, a significant increase of
the median annualized relapse rate was found in the year following fingolimod discontinuation
compared to the period before (p < 0.0001), and 57% of women experienced at least
one relapse.
When considering to start fingolimod, particular attention should be paid to women
with a short-term pregnancy desire.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical activity after fingolimod cessation: disease reactivation or rebound?.Eur. J. Neurol. 2018; 25: 1270-1275
- Disease exacerbation after the cessation of fingolimod treatment in japanese patients with Multiple Sclerosis.Intern. Med. 2018; 57: 2647-2655
- Disease reactivation after fingolimod discontinuation in pregnant Multiple Sclerosis patients.Neurotherapeutics. 2021; 18 (Epub 2021 Sep 7): 2598-2607https://doi.org/10.1007/s13311-021-01106-6
- Factors associated with fingolimod rebound: a single center real-life experience.Mult. Scler. Relat. Dis. 2021; 56103278
- Factors predictive of severe Multiple Sclerosis disease reactivation after fingolimod cessation.Neurologist. 2018; 23: 12-16
- Rebound of Multiple Sclerosis activity after fingolimod withdrawal due to planning pregnancy: analysis of predisposing factors.Mult. Scler. Relat. Dis. 2020; 38101483
- Rebound syndrome in patients with Multiple Sclerosis after cessation of fingolimod treatment.JAMA Neurol. 2016; 73: 790
- A comparison of Multiple Sclerosis disease activity after discontinuation of fingolimod and placebo.Mult. Scler. J. Exp. Transl. Clin. 2017; 32055217317730096
- Natalizumab, fingolimod, and dimethyl fumarate use and pregnancy-related relapse and disability in women with Multiple Sclerosis.Neurology. 2021; 96: e2989-e3002
- Relapse occurrence in women with Multiple Sclerosis during pregnancy in the new treatment era.Neurology. 2018; 90: e840-e846
Article info
Publication history
Published online: July 22, 2022
Accepted:
July 21,
2022
Received in revised form:
July 13,
2022
Received:
May 2,
2022
Identification
Copyright
© 2022 Elsevier B.V. All rights reserved.
